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Endothelin receptor antagonists influence cardiovascular mor- tients [1, 2]. Structural abnormalities of the cardiovascular
phology in uremic rats. system, for example, wall thickening of intramyocardial
Background. It is generally held that renal failure results and peripheral arteries, as well as increased myocardialin blood pressure (BP)-independent structural changes of the
fibrosis, have been documented in rats with experimentalmyocardium and the vasculature. The contribution, if any, of
chronic renal failure [3–6] and in patients with end-stageendothelin (ET) to these changes has been unknown.
Methods. We morphometrically studied random samples of renal disease [7]. These changes may have important func-
the left ventricle myocardium and small intramyocardial arter- tional consequences, such as reduced coronary reserve,
ies in subtotally (5/6) nephrectomized (SNx) male Sprague- reduced vascular and left ventricular compliance, andDawley rats treated with either the selective ETA receptor
increased mean arterial blood pressure (BP) [8–10]. Itantagonist BMS182874 (30 mg/kg/day) or the nonselective
is of note that the structural changes are, at least in part,ETA/ETB receptor antagonist Ro46-2005 (30 mg/kg/day) in
comparison with either sham-operated rats, untreated SNx, independent of the level of systemic BP [3–5, 11].
or SNx rats treated with the angiotensin-converting enzyme There is accumulating evidence that endothelin (ET),
inhibitor trandolapril (0.1 mg/kg/day).
a potent endogenous vasodilator and mitogenic agent,Results. Eight weeks later, systolic BP was lower in trandola-
is involved in chronic progressive renal failure [12–15]pril-treated SNx compared with untreated SNx animals. No
decrease in BP was seen following either ET receptor antago- and in cardiovascular disease [16–18]. Expression of all
nist at the dose used. A significantly increased volume density three ET isopeptides, predominantly ET-1, has been
of the myocardial interstitium was found in untreated SNx demonstrated in the mammalian heart, particularly inrats as compared with sham-operated controls. Such interstitial
cardiomyocytes [19, 20] and in the endocardium [21].expansion was prevented by trandolapril and either ET recep-
ET-1 is the only ET isopeptide that is generated in thetor antagonist. SNx caused a substantial increase in the wall
thickness of small intramyocardial arteries. The increase was endothelium and vascular smooth muscle cells (VSMCs)
prevented by trandolapril or BMS182874 treatment. The arteri- [22, 23]. Both the ETA and ETB receptor subtypes wereolar wall:lumen ratio was significantly lower in all treated
identified in the myocardium and endocardium as wellgroups when compared with untreated SNx. In contrast, only
as in VSMCs [24, 25]. The ETA receptors account fortrandolapril, but not the ET receptor antagonists, attenuated
thickening of the aortic media in SNx animals. approximately 80% of the total cardiac ET receptor pool
Conclusions. The ETA-selective and ETA/ETB-nonselective [26]. Nevertheless, ETB receptors have been reported to
receptor antagonists appear to prevent development of myo- be the major subtype in myocardial capillaries [27]. Acardial fibrosis and structural changes of small intramyocardial
role of ET has been postulated in the pathogenesis ofarteries in experimental chronic renal failure. This effect is
malignant hypertension [16, 28], coronary artery diseaseindependent of systemic BP.
[17, 29], and congestive heart failure [18, 30]. Its contribu-
tion, if any, to the development of myocardiopathy and
Cardiovascular abnormalities are known to be the vascular remodeling in renal failure remains obscure.
leading cause of morbidity and mortality in uremic pa- In this article, we selected the remnant kidney model
of renal failure and investigated the effect of ETA-selec-
tive and ETA/ETB-nonselective receptor antagonists onKey words: myocardial arteries, fibrosis, renal failure, subtotal ne-
phrectomy, uremia, blood pressure, hypertension. the structure of myocardium and of arterial vessels, both
of the muscular and elastic type. A particular effort wasReceived for publication January 20, 1998
made to examine whether a potential effect was depen-and in revised form August 6, 1998
Accepted for publication September 11, 1998 dent on changes in systemic BP and in left ventricular
mass. 1999 by the International Society of Nephrology
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METHODS smooth muscle cells separated from the endothelium by
a continuous basement membrane. The wall thicknessAnimals and experimental design
was determined as the mean of measurements of twoMale Sprague-Dawley rats weighing 200 to 230 g were
opposite walls. Measurements were taken at the sitefed a standard rat chow (19% protein, 0.25% sodium),
where the luminal diameter was minimal, because, atwith free access to tap water. The animals were allotted
this point, measurements are least affected by sectioningto five groups. The animals of group 1 (N 5 8) were
angle.sham-operated (decapsulation of the kidneys) and were
Cross-sections of the aorta descendens in the vicinityfurther left untreated. In groups 2 to 5, 5/6 subtotal ne-
of the aortic arc were prepared. Semithin (1 mm) sectionsphrectomy (SNx) was performed under isofluran inhala-
were cut, stained with methylene blue and basic fuchsin,tion anesthesia. After ablation of the right kidney, a
and studied planimetrically as mentioned earlier here atweek later, both poles of the left kidney were resected.
a magnification 325. The external and internal contoursFollowing the operation, the animals of group 2 (N 5 8)
of the media were outlined, and the media cross-sectionalreceived no treatment. As a positive control, group 3
area, media thickness, and lumen diameter were calcu-(N 5 8) received the angiotensin (Ang)-converting en-
lated.zyme (ACE) inhibitor trandolapril (Knoll, Ludwigsha-
fen, Germany) by gavage at a dose 0.1 mg/kg/day. Group 4 Statistics
(N 5 8) was treated with the orally active nonpeptide
Data are given as means 6 sem. Multiple intergroupETA receptor antagonist BMS182874 (Bristol-Myers
comparisons were made using the Kruskal–Wallis testSquibb, Princeton, NJ, USA) at a dose of 30 mg/kg/day.
followed by the Mann–Whitney U-test for pair-wise com-Group 5 (N 5 10) was treated with the orally active
parisons. The statistical analysis was carried out usingnonpeptide ETA/ETB-nonselective receptor antagonist
the SPSS software (SPSS Inc., Chicago, IL, USA). TheRo46–2005 (Hoffman-La Roche, Basel, Switzerland) at
null hypothesis was rejected if P was , 0.05.a dose of 30 mg/kg/day. The treatments in groups 3, 4,
and 5 continued over eight weeks. Body weight, systolic
BP measured by tail plethysmography, hematocrit, se- RESULTS
rum and urinary creatinine, and plasma renin activity
Characterization of the modelwere determined before surgery, four weeks later, and at
Some pertinent animal data at the end of the experi-the end of the experiment. Serum and urinary creatinine
ment are shown in Table 1. A significant increase inwere measured using the Jaffe´ reaction. Plasma renin
serum creatinine was noted in all SNx groups, and thisactivity was determined using a radioimmunoassay for
was paralleled by a decrease in creatinine clearance.angiotensin I (Ang I).
Hematocrit values were also lower in all SNx groups
Morphological techniques compared with sham-operated controls. Systolic BP was
significantly elevated in untreated SNx animals as com-The experiment was terminated by retrograde perfu-
pared with the controls. The increase in BP was pre-sion of the aldehyde fixative via the abdominal aorta as
vented by the ACE inhibitor trandolapril. By contrast,described in detail elsewhere [31]. The heart and aorta
no decrease in BP was seen with either the ETA-selectivewere excised, with the left ventricle separated, weighed,
or -nonselective ET receptor antagonist. The left ventri-and sliced perpendicular to the longitudinal axis. Two
cle weight:body weight ratio was substantially higher inslices of each left ventricle were randomly sampled and
the untreated SNx compared with the sham-operated orsectioned for stereologic investigation using the orienta-
trandolapril-treated groups. The groups treated with ETtor technique as described [32]. The resulting eight left
receptor antagonists did not significantly differ from con-myocardial pieces per animal were embedded in Epon-
trols. Significantly lower plasma renin activity was foundAraldite, and semithin (0.5 m) isotropic uniform random
in all SNx groups except the one treated with trandola-sections were made to be further stained with methylene
pril.blue and basic fuchsin. The sections were examined by
light microscopy with oil immersion and phase contrast
Morphological dataat a magnification 31,000. Volume density of the myo-
The volume density of the myocardial interstitiumcardial interstitium was measured in each section using
(cm3/cm3 3 102) was significantly higher (P , 0.01) inthe point counting method and was averaged for each
the untreated SNx group (2.89 6 0.16) compared withanimal. Wall thickness and lumen diameter of small (30
sham-operated controls (2.15 6 0.17; Fig. 1 A, B). Tran-to 70 m in diameter) intramyocardial arteries were as-
dolapril as well as the selective ETA receptor antagonistsessed by planimetry using a semiautomatic image analy-
BMS182874 and the nonselective ET receptor antagonistsis system (IBAS2; Contron, Eding, Germany). Arteries
were defined as vessels having a complete layer of Ro46-2005 prevented (P , 0.005) enlargement of the
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Table 1. Animal data
Creatinine Plasma renin
Serum clearance activity
Systolic BP LV wt: body wt creatinine ml/min/100 g Hct ng Ang
mm Hg 3 1023 lmol/liter body wt % I/ml/hr
Sham operated 13165.3a 1.9860.05a 30.762.5a 1.0860.2a 47.360.54a 13.362.92a
N 5 8
SNx untreated 170 68.6 2.2360.12 64.8 68.5 0.41 60.06 42.2 60.78 1.4660.22
N 5 8
SNx 1 trandolapril 12865.3a 1.9260.08a 60.163.2 0.43 60.05 39.4 60.74 8.33 62.13a
N 5 8
SNz 1 BMS182874 15464.9 2.1 60.04 57.664.7 0.5 60.06 39.262.19 2.0260.33
N 5 8
SNx 1 Ro46-2005 16767.6 2.2560.1 57.2 62.1 0.46 60.03 39.2 61.05 1.6260.55
N 5 10
Values are means 6 SEM. Abbreviations are: LV, left ventrical; Ang I, angiotensin I; SNx, subtotal nephrectomy.
a P , 0.05 vs. untreated SNx group
Fig. 1. Structural changes of the myocardium in subtotally nephrectomized (SNx) rats eight weeks after the start of the experiment. Representative
findings in sham-operated (A), untreated SNx (B), BMS182874-treated SNx (C), and Ro46-2005-treated SNx animals (D). These figures illustrate
the increase of interstitial tissue in the untreated SNx animal with the most prominent interstitial expansion (B) and the absence of intramyocardial
interstitial enlargement in sham (A) and both groups receiving the ET receptor antagonists (C and D). Semithin section, methylene blue—basic
fuchsin (magnification A, C, and D 3640; B, 31100).
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Table 2. Morphometric measurements of small 7, 31]. This increase in interstitial tissue is characterized
intramyocardial arteries
by a significant increase in mean cell and nuclear volume
Media Lumen
Wall:lumen of interstitial fibroblasts and activation of these cells withthickness diameter
ratio increased proliferating cell nuclear antigen positivity, en-
lm 310 m23 largement of the Golgi apparatus, and higher intracellu-
Sham operated 1.22 60.04a 32,660.83 4062a lar actin filament content [33]. The expansion of the
N 5 8 interstitial tissue could be prevented with ACE inhibitors
SNx untreated 1.55 60.07 33.260.81 4863
but not with calcium antagonists or sympathicolyticN 5 8
SNx 1 trandolapril 1.1960.04a 31.961.02 4062a agents [11]. In this study, we showed significantly lower
N 5 8 volume density of the myocardial interstitium after treat-
SNx 1 BMS182874 1.2360.03a 35.260.69 3761a
ment with either ETA-selective or ETA/ETB-nonselectiveN 5 8
SNx 1 Ro46-2005 1.4360.07 36.561.53a 4062a receptor antagonists in moderately severe chronic renal
N 5 10 failure. Although the dose–response relationship was not
Values are means 6 SEM. investigated, the effect of the chosen dose of the ET
a P , 0.05 vs. untreated Snx group
receptor antagonists was comparable with that of a typi-
cal dose of an ACE inhibitor.
Considerable information is available on the interac-
tion between ET and cardiac fibroblasts. ETs increaseinterstitium (2.0 6 0.16, 2.04 6 0.15, and 1.77 6 0.16,
the synthesis of type I and II collagens in adult rat cardiacrespectively; Fig. 1 C, D).
fibroblasts [34]. In addition, specific binding of ET-1 andTable 2 summarizes the results of the morphometric
ET-3 to cardiac fibroblasts has been documented sug-analysis of intramyocardial arterioles. A significant thick-
gesting the presence of both ETA and ETB receptor sub-ening of the vessel wall was found in untreated SNx
types [35]. In mouse fibroblasts and in VSMCs of rabbitcompared with sham-operated controls (Fig. 2 A, B).
aorta, long-lasting activation of cation current by veryNo increase in the wall thickness was noted in trandola-
low concentrations of ET-1 was found [36].pril- or BMS182874-treated groups (Fig. 2 C, D). The
In addition, another hallmark of uremia, that is, walldifference between SNx 1 Ro46-2005 and untreated SNx
thickening of intramyocardial arteries [3–5], was simi-failed to reach statistical significance. Of note, the mean
larly ameliorated by the ETA-selective receptor antago-arterial lumen diameter was highest in the SNx 1 Ro46-
nist as by the ACE inhibitor trandolapril. A similar trend2005 group. Nevertheless, the wall:lumen ratio was sig-
was also observed with the nonselective ET receptornificantly lower in all treated groups irrespective of the
antagonist, although the difference was not statisticallysubstance applied.
significant. Wall thickening of intramyocardial arteriesTable 3 represents the data on aortic structure in the
in SNx was found to be due to hypertrophy of VSMCsdifferent experimental groups. Cross-sectional area and
with a significant increase in cell and nuclear volumethickness of the media were substantially higher in un-
compared with sham-operated controls [To¨rnig et al,treated SNx (Fig. 3B) when compared with sham-oper-
unpublished data]. Perivascular fibrosis was not involvedated controls (Fig. 3A). The wall thickening was partly
in the increase of arteriolar wall thickness in renal failure.prevented by trandolapril administration (Fig. 3C). In
Apparently, the behavior of blood vessels is quite hetero-contrast, the two ET receptor antagonists did not affect
geneous in renal failure. In another study, we examinedaortic wall thickness (Fig. 3 D, E). The changes of wall:lu-
the aorta (as a model of an elastic artery) in renal failuremen ratio went in parallel with the changes of the media.
and found hyperplasia with only modest hypertrophy of
VSMCs [38].
DISCUSSION Enhanced expression of ET in the myocardium and
The involvement of ET in the progression of renal vascular endothelium has previously been demonstrated
insufficiency and conversely a renoprotective role of ET in experimental models of arterial hypertension [21, 39–
receptor antagonists have been recently recognized in 41] or cardiovascular pathology [29, 42]. Using quantita-
studies on the remnant kidney model [12–15]. Whether tive polymerase chain reaction, an increased prepro-
ET is also involved in the genesis of cardiovascular com- ET-1 mRNA level has also been recently found in the
plications of renal failure has not been documented so myocardium of SNx rats (unpublished data). The vaso-
far. The results of this study argue for a role of ET in constrictive [22] and promitogenic [43, 44] actions of ET
the structural changes seen in the heart, but not in those might be involved in the genesis of myocardial fibrosis.
occurring in the aorta. It is of note that the attenuation of fibrosis was seen,
Both in humans and in laboratory animals, uremia is although the two ET receptor antagonists failed to pre-
characterized by activation of cardiac fibroblasts fol- vent left ventricular hypertrophy in uremic rats. Because
both ETA-selective and ETA/ETB-nonselective receptorlowed by intercardiomyocytic interstitial expansion [6,
Fig. 2. Structural changes of small intramyocardial arteries in SNx rats eight weeks after the start of the experiment. Representative arteriolar
sections of sham-operated (A), untreated SNx (B), trandolapril-treated SNx (C), and BMS182874-treated SNx animals (D). The arteriolar wall
thickness is considerably greater in SNx (B) than in sham operated animals (A) and animals of the two treated SNx groups (C and D). Semithin
section, methylene blue–basic fuchsin (magnification 3640).
Fig. 3. Structural changes of the aorta in SNx rats eight weeks after the start of the experiment. Representative sections of the aortic wall of sham-
operated (A), untreated SNx (B), trandolapril-treated SNx (C), BMS182874-treated SNx (D), and Ro46-2005–treated SNx animals (E). An increase
in media thickness is observed in untreated SNx animals (B). Such an increase is attenuated in SNx animals treated with trandolapril (C), but not in
SNx animals treated with either ET receptor antagonist (D and E). Semithin sections, methylene blue–basic fuchsin (magnification 3320).
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Table 3. Morphometric parameters of the aorta have beneficial effects on the cardiovascular abnormali-
ties in renal failure. The question arises as to whetherMedia cross- Media Lumen Wall:lumen
sectional area thickness diameter ratio ET and Ang II interact in effecting initiation and pro-
mm2 lm mm 3 1023 gression of the structural changes of the heart. In fact,
Sham operated 0.5160.02a 8462a 1.8560.05 4562a Ang II increases prepro-ET-1 mRNA expression in en-
N 5 8
dothelial cells [49, 50], VSMCs [51], and cardiomyocytesSNx untreated 0.6660.03 107 65 1.8660.06 58 63
N 5 8 [20]. Furthermore, Ang II up-regulates ETB receptors in
SNx 1 trandolapril 0.5860.06a 9267a 1.8960.04 4963a rat cardiomyocytes [52]. On the other hand, in cultured
N 5 8
endothelial cells exposed to ET, conversion of Ang I toSNx 1 BMS182874 0.760.04 10664 1.9960.06 53 62
N 5 8 Ang II is increased [53]. ACE inhibitors (a) prevented
SNx 1 Ro46-2005 0.7660.03 11564 1.9860.04 59 63 hemodynamic changes following administration of exog-
N 5 10
enous ET to experimental animals [54, 55] and humans
Values are means 6 SEM. [56], (b) abolished ET-induced early growth response inaP , 0.05 vs. untreated SNx group
isolated myocardial cells [57], (c) decreased ET-1 libera-
tion from cultured human endothelial cells [58], and (d)
reduced ET-1 plasma concentration in hypertensive pa-
tients [59]. The Ang II receptor antagonist losartan re-antagonists were equally effective, a specific role of the
ETA receptor is suggested. duced ET-1 expression in the aorta and peripheral arter-
ies of SNx rats [60]. Conversely, the ETA receptorArterial hypertension is considered to be a major
cause of vascular remodeling in uremia, although vessel antagonist BQ-123 inhibited Ang II–induced contraction
of the rabbit aorta [61]. These findings are in line withwall thickening cannot be completely prevented by BP
lowering [3–5]. This study documents prevention of wall our observations that ACE inhibitors and ET receptor
antagonists have similar effects on the structural changesthickening of intramyocardial resistance vessels by the
ETA receptor antagonist independent of BP. This obser- of the heart in uremia. Based on the previously men-
tioned observations that indicate interaction of the renin-vation is in agreement with some recent data on effects
of nonselective ET receptor antagonists in other hyper- angiotensin system and ET system, one would anticipate
additional benefit from combining ACE inhibitors andtensive models, for example, DOCA-salt hypertensive
rats [45] or DOCA-salt spontaneously hypertensive rats ET receptor blockers. A combination of both drugs,
however, did not increase the benefit, at least at the[46]. We admit, however, that we performed plethysmo-
graphic BP measurements only. In the absence of tele- doses used in this experiment (unpublished data).
In contrast, additive effects of administration of themetric BP monitoring, we cannot exclude some change
of the 24-hour-averaged BP level [47]. Nevertheless, the ACE inhibitor cilazapril and the mixed ET receptor an-
tagonist bosentan on the mean BP have been recentlyseverity of left ventricular hypertrophy went in parallel
with the systolic BP values measured by plethysmo- shown in rats with chronic heart failure [62], and the
same appears to be true for prevention of glomeruloscle-graphy, lending further credence to the registered differ-
ences in BP between the groups. rosis [63].
A potential role of the bradykinin system in the devel-One further observation argues against the idea that
left ventricular hypertrophy is simply the reaction of the opment of cardiac structural changes is supported by the
unpublished finding in one of our experimental studiesleft ventricle to increased afterload. Although the small
wall thickness of the right ventricle prevents quantitative [64] that the bradykinin receptor antagonist HOE 140
prevents left ventricular hypertrophy after SNx.measurements with the orientator method, qualitative
observations showed cardiomyocyte hypertrophy, ex- In contrast to the changes in the heart, the abnormali-
ties in the aortic wall of uremic animals were not affectedpansion of the interstitium and arteriolar wall thickening,
as well as expression of renin and ET-1 message and by either of the ET receptor antagonists used. This obser-
vation is in accord with studies performed in DOCA-ET-1 protein in the right ventricle as well.
It was not the purpose of this study to elucidate the salt hypertensive rats [65, 66]. Decreased density of aor-
tic ET-1 receptors has been documented in these animalsmechanisms underlying the beneficial cardiac effect of
the ET receptor antagonists in this model. Both hyper- [67] and may explain the inefficacy of ET receptor antag-
onists in this model. Whether the same is true in experi-trophy and hyperplasia of VSMCs have been implicated
in the arterial wall thickening in renal failure [38]. ET- mental uremia is unknown. At any rate, in experimental
uremia, the effect of ET receptor antagonists on small1 exerts hypertrophic and mitogenic actions in VSMCs
via ETA receptors [48, 49]. It is reasonable to assume that resistance arteries is distinctly different from that on
large conduit vessels.reversal of such effects played a role in the prevention of
the wall thickening of small intramyocardial arteries. In summary, myocardial fibrosis and abnormalities of
the structure of small intramyocardial arteries in moder-Both ET receptor antagonists and ACE inhibitors
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